Assessing Genpact (G) Valuation After Recent Share Price Weakness

Genpact overview and recent performance snapshot

Genpact (G) has been on some investors’ radar after recent share price softness, with the stock around $38.92 and negative returns over the past month, past 3 months, year to date, and past year.

See our latest analysis for Genpact.

At a share price of $38.92, Genpact’s recent 1 day share price return of a 4.75% decline and 90 day share price return of a 16.05% decline point to fading momentum, which aligns with its 1 year total shareholder return of a 20.67% decline.

If this pullback has you looking wider than a single name, it could be a good moment to see what else is out there via our 20 top founder-led companies.

With Genpact trading at $38.92, an indicated 65.59% intrinsic discount and a roughly 25% gap to the average analyst target, you have to ask whether this is a genuine mispricing or whether the market is already factoring in future growth.

Most Popular Narrative: 20% Undervalued

Genpact's widely followed narrative pegs fair value at about $48.64 per share, compared with the last close of $38.92. This sets up a clear valuation gap for investors to examine.

Demand for end to end digital transformation, evidenced by Genpact's strong partnerships with leading cloud providers (AWS, Salesforce, ServiceNow) and rapidly growing pipeline of annuitized, non-FTE revenue streams (70% of Advanced Tech Solutions revenue), is likely to support increasingly resilient, high-quality earnings growth.

Read the complete narrative.

Curious what underpins that higher fair value? The narrative leans on steady revenue expansion, firmer profit margins, and a future earnings multiple that still sits below many peers. Want to see how those moving parts fit together in the model?

Result: Fair Value of $48.64 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, slowing legacy BPO growth and tougher competition for AI rich, outcome based contracts could weigh on margins and make those valuation assumptions harder to achieve.

Find out about the key risks to this Genpact narrative.

Next Steps

With that mix of concern and optimism in mind, do not wait on someone else’s conclusion. Check the positives for yourself, starting with 5 key rewards.

Looking for more investment ideas?

If Genpact has you thinking harder about where your money is working, do not stop here. Broaden your opportunity set with a few focused stock ideas.

• Target value by checking companies on our 48 high quality undervalued stocks that currently look cheaper than their underlying fundamentals might suggest.
• Strengthen your income stream by reviewing the 14 dividend fortresses that may suit investors who want higher yields with a clear focus on resilience.
• Prioritize stability by scanning companies in the 68 resilient stocks with low risk scores that score well on financial risk and balance sheet strength.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com